How to watch 'Contact in the Desert' online – live stream UFO conference from anywhere
"Contact in the Desert" – billed as "the world's largest UFO and UAP conference" – features some of the brightest stars from 'UFO Twitter', including Ross Coulthart and George Knapp. Can't make it to the Woodstock of UFOlogy? Those without a ticket can watch it live online...
Here's how to watch "Contact in the Desert" live streams from from anywhere with a VPN.
"Contact in the Desert" takes place May 29 – June 2, 2025. Streaming passes from $149 (using discount code 'TOMS').• WATCH LIVE — PursingX• Watch anywhere — try NordVPN 100% risk-free
Is there really any truth to the rumor that "non-human intelligence" (aliens) exist? While Congress continues to investigate the rumors of UFO crash retrivals, "Contact in the Desert" is here to bring you up to date with everything UFO/UAP.
Themed "Event Horizon," the 2025 event takes place at the Renaissance Esmeralda Resort & Spa in Indian Wells, California. It offers over 50 sessions exploring topics like extraterrestrial life, AI, space travel, and consciousness. Keynote speaker Josh Gates, of "Expedition Unknown", will present on May 31.
"CITD" also features renowned figures such as NewsNation's Ross Coulthart, "The Telepathy Tapes'" Dr. Diane Hennacy Powell, and UFO O.G. George Knapp, the man who uncovered Bob Lazar's truly wild claims about Area 51. Attendees can participate in workshops, night sky excursions, and live podcast recordings.
Can't make it in person? You can buy an online streaming pass. Here's how to watch and stream "Contact in the Desert" 2025 live online.
Whether you're in the States or further afield, you can watch "Contact in the Desert" live on the PursuingX streaming platform.
There are a range of passes but for the best experience, there's the Ultimate Replay + Live pass costing $499. This gets you all the live streams, plus all the replays. It's like being there... without being there.
Only want the live stream? Opt for the Live Stream pass costing $199.
Not exactly cheap. But then again, it considered to be the hottest ticket in 'UFO town'.
Discount code: You can get $50 off the Ultimate Replay + Live pass by using the code 'TOMS' when you get to the checkout page. There's also $25 off the Live Stream pass.
Abroad? If you're traveling, or want to watch securely and privately, use a VPN. We recommend NordVPN (save 70%).
Away from home at the moment and blocked from watching content on your usual streaming service? Or prefer to watch things online privately and securely?
You can watch "Contact in the Desert" safely and from anywhere thanks to the wonders of a VPN (Virtual Private Network). The software allows your devices to appear to be back in your home country. Our favorite is NordVPN.
There's a good reason you've heard of NordVPN. We specialize in testing and reviewing VPN services and NordVPN is the one we rate best. It's outstanding at unblocking streaming services, it's fast and it has top-level security features too. With over 7,000 servers, across 110+ countries, and at a great price too, it's easy to recommend.
Get 70% off with this NordVPN deal
Using a VPN is incredibly simple.
1. Install the VPN of your choice. As we've said, NordVPN is our favorite.
2. Choose the location you wish to connect to in the VPN app. For instance, if you're in Australia and want to view your usual U.S. service, you'd select U.S. from the list.
3. Sit back and enjoy the action. Fire up your usual website or streaming service and tune into content as if you were back in your home country.
Yes! You can watch the live stream by paying for one of the passes. They're listed in dollars but to give you an idea:
The Ultimate Replay + Live pass costs $499 (around £370). This gets you all the live streams, plus all the replays.
For the live stream only, then go for the Live Stream pass costing $199 (around £145).
Discount code: You can $50 off the Ultimate Replay + Live pass and $25 off the Live Stream pass by using the code 'TOMS' at the checkout.
Again, if you're traveling or want to watch the stream securely, we strongly recommend getting NordVPN (save 70%).
You can view the live streams and videos "from any Internet connected device." You can also listen from your smartphone, laptop, desktop computer (Windows or Mac), tablet (iOS/Android) or smart TV.
Please note that security settings will prevent you from using a simulcast system.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
27 minutes ago
- Business Wire
U.S. FDA Approves NUBEQA ® (darolutamide) to Treat Patients with Metastatic Castration-Sensitive Prostate Cancer
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved its oral androgen receptor inhibitor (ARi) NUBEQA ® (darolutamide) for the treatment of adult patients with metastatic castration-sensitive prostate cancer (mCSPC), which is also known as metastatic hormone-sensitive prostate cancer (mHSPC). The approval is based on positive results from the pivotal Phase III ARANOTE trial, which demonstrated a significant reduction of 46% in the risk of radiographic progression or death (rPFS) for those treated with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT (hazard ratio [HR] 0.54; 95% CI 0.41-0.71; p<0.0001). 1 The randomized, double-blind, placebo-controlled Phase III ARANOTE trial was designed to assess the efficacy and safety of NUBEQA plus ADT in patients with mCSPC. 1 A total of 669 patients were randomized 2:1 to receive either 600 mg of NUBEQA (N=446) or placebo (N=223) twice daily in addition to ADT. 1 NUBEQA is indicated in the U.S. for the treatment of adult patients with mCSPC, both with and without docetaxel, and for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC). 2 'Clinical data from the ARANOTE trial supporting this new regimen showed that NUBEQA plus ADT demonstrated powerful efficacy in men with mCSPC,' said Fred Saad, M.D., Professor and Chairman of Surgery and Director of Genitourinary Oncology at the University of Montreal Hospital Center (CHUM) and principal investigator of the ARANOTE trial. 'Today's approval further expands physicians' options for using NUBEQA with and without docetaxel in this setting, providing a potential new choice for patients.' Prostate cancer is the second most common cancer in men and the fifth most common cause of cancer death in men worldwide. 3 In 2020, an estimated 1.4 million men worldwide were diagnosed with prostate cancer, including nearly 300,000 in the U.S., and about 375,000 men died from the disease worldwide. 4,5 Prostate cancer diagnoses are projected to increase to 2.9 million worldwide by 2040. 6 'This approval, which is supported by strong clinical data, reaffirms NUBEQA as an important therapy for men with prostate cancer and underscores our commitment to delivering meaningful outcomes for patients and their families,' said Christine Roth, Executive Vice President, Global Product Strategy and Commercialization and Member of the Pharmaceuticals Leadership Team at Bayer. 'We thank the scientists, doctors, patients and their families who made it possible to provide this new treatment option for metastatic castration-sensitive prostate cancer.' Results from the Phase III ARANOTE trial, presented at the 2024 European Society for Medical Oncology (ESMO) Congress and published in The Journal of Clinical Oncolog y. 1 Results of the radiographic progression-free survival (rPFS) analysis were consistent across prespecified subgroups, including a 40% risk reduction (HR 0.60, 95% CI: 0.44-0.80) with NUBEQA plus ADT in patients with high-volume mCSPC and a 70% risk reduction (HR 0.30, 95% CI: 0.15-0.60) in patients with low-volume disease. 1 The results were consistent with the established safety profile of NUBEQA. Rates of serious adverse events were similar between the treatment arms (24% for NUBEQA plus ADT compared to 24% for placebo plus ADT). 1,2 Discontinuation due to treatment-emergent adverse events (TEAEs) was 6% for patients treated with NUBEQA plus ADT compared to 9% in patients receiving placebo plus ADT. 1,2 About the ARANOTE Trial 7 The randomized, double-blind, placebo-controlled Phase III ARANOTE trial study assessed the efficacy and safety of NUBEQA plus ADT in patients with mCSPC. A total of 669 patients were randomized to receive 600 mg of NUBEQA twice daily or matching placebo in addition to ADT. The primary endpoint was rPFS, measured as time from randomization to date of first documented radiographic progressive disease or death due to any cause, whichever occurs first. About NUBEQA ® (darolutamide) 2 NUBEQA ® (darolutamide) is an androgen receptor inhibitor (ARi) with a distinct chemical structure that competitively inhibits androgen binding, AR nuclear translocation, and AR-mediated transcription. NUBEQA was developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company. NUBEQA is an androgen receptor inhibitor indicated for the treatment of adult patients with: Non-metastatic castration-resistant prostate cancer (nmCRPC) Metastatic castration-sensitive prostate cancer (mCSPC) Metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel IMPORTANT SAFETY INFORMATION Warnings & Precautions Ischemic Heart Disease – Ischemic heart disease, including fatal cases, occurred in patients receiving NUBEQA. In a pooled analysis of ARAMIS and ARANOTE, ischemic heart disease occurred in 3.4% of patients receiving NUBEQA and 2.2% receiving placebo, including Grade 3-4 events in 1.4% and 0.3%, respectively. Ischemic events led to death in 0.4% of patients receiving NUBEQA and 0.4% receiving placebo. In ARASENS, ischemic heart disease occurred in 3.2% of patients receiving NUBEQA with docetaxel and 2% receiving placebo with docetaxel, including Grade 3-4 events in 1.3% and 1.1%, respectively. Ischemic events led to death in 0.3% of patients receiving NUBEQA with docetaxel and 0% receiving placebo with docetaxel. Monitor for signs and symptoms of ischemic heart disease. Optimize management of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidemia. Discontinue NUBEQA for Grade 3-4 ischemic heart disease. Seizure – Seizure occurred in patients receiving NUBEQA. In a pooled analysis of ARAMIS and ARANOTE, Grade 1-3 seizure occurred in 0.2% of patients receiving NUBEQA. Seizure occurred from 261 to 665 days after initiation of NUBEQA. In ARASENS, seizure occurred in 0.8% of patients receiving NUBEQA with docetaxel, including two Grade 3 events. Seizure occurred from 38 to 1754 days after initiation of NUBEQA. It is unknown whether anti-epileptic medications will prevent seizures with NUBEQA. Advise patients of the risk of developing a seizure while receiving NUBEQA and of engaging in any activity where sudden loss of consciousness could cause harm to themselves or others. Consider discontinuation of NUBEQA in patients who develop a seizure during treatment. Embryo-Fetal Toxicity – The safety and efficacy of NUBEQA have not been established in females. NUBEQA can cause fetal harm and loss of pregnancy. Advise males with female partners of reproductive potential to use effective contraception during treatment with NUBEQA and for 1 week after the last dose. Adverse Reactions In ARAMIS, serious adverse reactions occurred in 25% of patients receiving NUBEQA and in 20% of patients receiving placebo. Serious adverse reactions in ≥1% of patients who received NUBEQA included urinary retention, pneumonia, and hematuria. Fatal adverse reactions occurred in 3.9% of patients receiving NUBEQA and 3.2% of patients receiving placebo. Fatal adverse reactions that occurred in ≥2 patients who received NUBEQA included death (0.4%), cardiac failure (0.3%), cardiac arrest (0.2%), general physical health deterioration (0.2%), and pulmonary embolism (0.2%). The most common (>2% with a ≥2% increase compared to placebo) adverse reactions, including laboratory test abnormalities, were increased AST (23%), decreased neutrophil count (20%), fatigue (16%), increased bilirubin (16%), pain in extremity (6%), and rash (4%). Clinically relevant adverse reactions occurring in 2% or more of patients treated with NUBEQA included ischemic heart disease (4%) and heart failure (2.1%). In ARANOTE, serious adverse reactions occurred in 24% of patients receiving NUBEQA. Serious adverse reactions in ≥1% of patients who received NUBEQA included pneumonia (2%), urinary tract infection (1.8%), musculoskeletal pain (1.6%), hemorrhage (1.6%), arrhythmias (1.3%), and spinal cord compression (1.1%). Fatal adverse reactions occurred in 4.7% of patients receiving NUBEQA and those that occurred in ≥2 patients included sepsis (1.1%), craniocerebral injury (0.4%), and myocardial infarction (0.4%). The most common (≥10% with a ≥2% increase compared to placebo) adverse reaction is urinary tract infection (12%). The most common laboratory test abnormalities (≥15% with a ≥5% increase over placebo) are increased AST (32%), increased ALT (28%), increased bilirubin (17%), and decreased neutrophil count (16%). Clinically relevant adverse reactions in <10% of patients who received NUBEQA included arrhythmia (8.8%), pneumonia (3.6%), and myocardial infarction (0.7%). In ARASENS, serious adverse reactions occurred in 45% of patients receiving NUBEQA with docetaxel. Serious adverse reactions in ≥2% of patients who received NUBEQA with docetaxel included febrile neutropenia (6%), neutrophil count decreased (2.8%), musculoskeletal pain (2.6%) and pneumonia (2.6%). Fatal adverse reactions occurred in 4% of patients receiving NUBEQA with docetaxel. Fatal adverse reactions in ≥2 patients who received NUBEQA included COVID-19/COVID-19 pneumonia (0.8%), myocardial infarction (0.3%), and sudden death (0.3%). The most common (≥10% with a ≥2% increase over placebo with docetaxel) adverse reactions are constipation (23%), rash (20%), decreased appetite (19%), hemorrhage (18%), increased weight (18%), and hypertension (14%). The most common laboratory test abnormalities (≥30%) are anemia (72%), hyperglycemia (57%), decreased lymphocyte count (52%), decreased neutrophil count (49%), increased AST (40%), increased ALT (37%), and hypocalcemia (31%). Clinically relevant adverse reactions in <10% of patients who received NUBEQA with docetaxel included fractures (8%), ischemic heart disease (3.2%), seizures (0.6%), and drug-induced liver injury (0.3%). Drug Interactions Effect of Other Drugs on NUBEQA – Concomitant use of NUBEQA with a combined P-gp and strong or moderate CYP3A4 inducer decreases darolutamide exposure which may decrease NUBEQA activity. Avoid concomitant use of NUBEQA with combined P-gp and strong or moderate CYP3A4 inducers. Concomitant use of NUBEQA with a combined P-gp and strong CYP3A4 inhibitor increases darolutamide exposure which may increase the risk of NUBEQA adverse reactions. Monitor patients more frequently for NUBEQA adverse reactions and modify NUBEQA dosage as needed. Effects of NUBEQA on Other Drugs – NUBEQA is an inhibitor of BCRP transporter. Concomitant use of NUBEQA increases the AUC and C max of BCRP substrates, which may increase the risk of BCRP substrate-related toxicities. Avoid concomitant use with drugs that are BCRP substrates where possible. If used together, monitor patients more frequently for adverse reactions, and consider dose reduction of the BCRP substrate drug. NUBEQA is an inhibitor of OATP1B1 and OATP1B3 transporters. Concomitant use of NUBEQA may increase the plasma concentrations of OATP1B1 or OATP1B3 substrates. Monitor patients more frequently for adverse reactions of these drugs and consider dose reduction while patients are taking NUBEQA. Review the Prescribing Information of drugs that are BCRP, OATP1B1, and OATP1B3 substrates when used concomitantly with NUBEQA. For important risk and use information about NUBEQA, please see the accompanying full Prescribing Information. About Metastatic Castration-Sensitive Prostate Cancer Prostate cancer is the second most common cancer in men and the fifth most common cause of cancer death in men worldwide. 3 In 2020, an estimated 1.4 million men worldwide were diagnosed with prostate cancer, including nearly 300,000 men in the U.S., and nearly 375,000 men died from the disease worldwide. 4,5 At the time of diagnosis, most men have localized prostate cancer, in which their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. Upon relapse when the disease will metastasize or spread, androgen deprivation therapy (ADT) is the cornerstone of treatment for this castration-sensitive, or hormone-sensitive, disease. Approximately 10% of men will already present with metastatic castration-sensitive prostate cancer (mCSPC), also known as metastatic hormone-sensitive prostate cancer (mHSPC), when first diagnosed. 8,9,10 Men with mCSPC will start their treatment with hormone therapy, such as ADT, an androgen receptor inhibitor (ARi) plus ADT, or a combination of the chemotherapy docetaxel and ADT. Despite this treatment, most men with mCSPC will eventually progress to castration-resistant prostate cancer (CRPC), which is associated with limited survival. 11,12 About Oncology at Bayer Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer includes six marketed products and several other assets in various stages of clinical development. Together, these products reflect the company's approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, 'Health for all, Hunger for none,' the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to © 2025 Bayer BAYER, the Bayer Cross and NUBEQA are registered trademarks of Bayer. Find more information at Our online press service is just a click away: Follow us on Facebook: Follow us on X: Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports, which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. References Saad F, et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the Phase III ARANOTE trial. J Clin Onc. 2024;42(36):4271-4281. NUBEQA ® (darolutamide) [Prescribing Information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; June 2025. Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Accessed June 2025. Prostate Cancer: Statistics. Accessed June 2025. American Cancer Society. Cancer Facts & Figures 2024. Accessed June 2025. James ND, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403:1683-1722. NCT04736199. Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer (ARANOTE). Accessed June 2025. Piombino C, et al. De novo metastatic prostate cancer: are we moving toward a personalized treatment? Cancers (Basel). 2023;15(20):4945. Helgstrand JT, et al. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer - A population-based analysis of 2 national cohorts. Cancer. 2018;124(14):2931-2938. Buzzoni C, et al. Metastatic prostate cancer incidence and prostate-specific antigen testing: new insights from the European Randomized Study of Screening for Prostate Cancer. Eur Urol. 2015;68:885-890. Siegel DA, et al. Prostate cancer incidence and survival, by stage and race/ethnicity - United States, 2001-2017. MMWR Morb Mortal Wkly Rep. 2020;69:1473-1480. Hahn AW, et al. Metastatic castration sensitive prostate cancer: optimizing patient selection and treatment. Am Soc Clin Oncol Educ Book. 2018;23;38:363-371.
New York Times
35 minutes ago
- New York Times
Sharp Hike in Nuclear Arms Budget Sought as Science Funding Is Slashed
The White House is asking Congress for a major jump in the nation's budget for designing, making, maintaining and reconditioning its nuclear arms. According to a budget justification sent in recent days to Congress, the Trump administration wants the annual spending on the weapon activities of the National Nuclear Security Administration to increase from $19 billion this year to roughly $30 billion in the 2026 fiscal year, a rise of 58 percent. The document calls the hike 'a historic investment' in the nuclear enterprise. Currently, the complex of facilities employs 65,500 people at eight main sites from coast to coast. The justification document was sent to Congress by the Energy Department, which oversees the semiautonomous nuclear security agency. The White House request comes as the Trump administration seeks to slash budgets in many other agencies that specialize in scientific research, including NASA, the Department of Health and Human Services, the Environmental Protection Agency and the National Science Foundation. Critics have accused the administration of cutting back research at the forefront of human knowledge, and the proposed nuclear investment seems likely to intensify those objections. Want all of The Times? Subscribe.
Yahoo
4 hours ago
- Yahoo
Gin Blossoms to push for patients' rights in pre-Congressional Baseball Game concert
The Gin Blossoms are aiming for lawmakers to follow them down the road to health care price transparency with a performance ahead of next week's Congressional Baseball Game. The alternative rockers behind '90s hits such as 'Hey Jealousy' and 'Til I Hear it From You' will take to the stage at the Bullpen in Washington just before first pitch between Democrats and Republicans at Congress's annual charity baseball competition on June 11 at Nationals Park. 'It'll be nice to play this show. It's a good event and it's a worthy cause,' Jesse Valenzuela, the Gin Blossoms' guitarist and singer, said in an interview this week with ITK. The band is performing on behalf of the nonprofit organization, Power to the Patients, which describes itself as a 'bipartisan movement to strengthen healthcare price transparency rules that will protect patients and unleash choice and competition to lower costs.' 'It's sort of a common-sense issue that they really want to get some sort of transparency on medical bills to people so that they don't wind up getting sick and going bankrupt trying to pay all the bills,' Valenzuela said. The 63-year-old songwriter mentioned his mother, who just celebrated a birthday this week: 'She's in her eighties, so she has health issues and concerns. And sometimes it can be difficult for people when there's more bill than she suspected, being on a fixed income.' 'We all make our way through these things, but sometimes, for some people, it can be catastrophic,' the 'Follow You Down' musician said. Power to the Patients has brought a star-studded lineup to the nation's capital over the years to advocate for healthcare price transparency and legislation, including rapper Fat Joe, Foo Fighters and Everclear, among others. A limited number of free tickets to the pre-Congressional Baseball Game festivities are available to the public through the Power to the Patients' website. Valenzuela, who's getting ready to hit the road as part of a nationwide tour this summer with Blues Traveler and the Spin Doctors, said he suspects the Gin Blossoms have some fans in Congress. 'I bet there are a few,' he said with a laugh. 'We're certainly of the right age.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
